ShiNung Ching, PhD, co-lead of NEURO360’s Mobile Apps, Software & Computing Research Node and a professor of neuroengineering, has been named chair of the Preston M. Green Department of Electrical & Systems Engineering at Washington University in St. Louis.
The Q4 edition of the NEURO360 newsletter highlights key findings from nine community listening sessions conducted across the St. Louis region in …
Over the past year, the NEURO360 team worked with its partner, the St. Louis Integrated Health Network (IHN) to host nine community …
NEURO360‑aligned research by Muriah D. Wheelock and Brian A. Gordon at WashU Medicine received a $5 million NIH grant to study how early‑life stress affects brain aging and Alzheimer’s.
NEURO360‑aligned research by Muriah D. Wheelock and Brian A. Gordon at WashU Medicine received a $5 million NIH grant to study how early‑life stress affects brain aging and Alzheimer’s.
Lan Yang has been named one of the world’s most highly cited researchers by the Institute for Scientific Information, ranking among the top 1% in her field over the past decade.
Jeff Milbrandt, MD, PhD, has been awarded the inaugural WashU Medicine Dean’s Medal for Innovation and Commercialization, recognizing his transformative discoveries in neurodegeneration and his leadership in translating breakthrough science into therapies.
NEURO360 partner work led by Randall J. Bateman, MD, is advancing global Alzheimer’s prevention trials through WashU’s DIAN-TU, which is testing whether anti-amyloid antibody therapies can stop the disease before symptoms begin.
A randomized controlled trial has demonstrated clinically meaningful improvements in...
Read More
Researchers at Washington University in St. Louis are developing a...
Read More
A randomized controlled trial has demonstrated clinically meaningful improvements in...
Read More
By combining advanced vision-language AI models with real-world task analysis,...
Read More
By combining advanced vision-language AI models with real-world task analysis,...
Read More
Research from WashU Medicine reports encouraging long-term results for tofersen,...
Read More
Research at Washington University in St. Louis has been recognized...
Read More
NEURO360-aligned research led by Rohit V. Pappu, PhD, with Min...
Read More
ShiNung Ching, PhD, co-lead of NEURO360’s Mobile Apps, Software &...
Read More
NEURO360‑aligned research by Muriah D. Wheelock and Brian A. Gordon at WashU Medicine received a $5 million NIH grant to study how early‑life stress affects brain aging and Alzheimer’s.
Lan Yang has been named one of the world’s most highly cited researchers by the Institute for Scientific Information, ranking among the top 1% in her field over the past decade.
Jeff Milbrandt, MD, PhD, has been awarded the inaugural WashU Medicine Dean’s Medal for Innovation and Commercialization, recognizing his transformative discoveries in neurodegeneration and his leadership in translating breakthrough science into therapies.
NEURO360 partner work led by Randall J. Bateman, MD, is advancing global Alzheimer’s prevention trials through WashU’s DIAN-TU, which is testing whether anti-amyloid antibody therapies can stop the disease before symptoms begin.
Saint Louis University’s Jenna Gorlewicz, Ph.D., has been named to the St. Louis Business Journal’s prestigious 40 Under 40 list, recognizing her leadership in engineering, research, and community impact.
A group of researchers from WashU in the McKelvey School of Engineering and the School of Medicine have created a new kind of fiber-optic device to manipulate neural activity deep in the brain. The device, called PRIME fiber, delivers multi-site, reconfigurable optical stimulation through a single, hair-thin implant.
Dr. Eric Leuthardt, neurosurgeon, scientist, entrepreneur, and co-leader of NEURO360, is advancing neurotechnology in St. Louis by translating groundbreaking research into life-changing solutions, launching companies like Neurolutions and Aurenar, and building a city-wide neurotech ecosystem.
A $3.2M NIH grant will support groundbreaking AI-driven research by WashU’s Ganesh Chand, PhD, to uncover mechanisms behind neuropsychiatric symptoms in Alzheimer’s.
NEURO360 took center stage at the 2025 BioSTL Global Health Innovation Summit in St. Louis, featuring a half-day dedicated to neuroscience innovation. Panels, startup showcases, and translation-to-practice discussions highlighted St. Louis as an emerging global hub for brain health breakthroughs.
NEURO360 partner, C2N Diagnostics, is set to occupy just over …
NEURO360 partner, Avadel Pharmaceuticals, is expanding its sleep medicine pipeline …
St. Louis Magazine highlights NEURO360’s vision to position St. Louis as a national leader in neuroscience and neurotechnology, uniting WashU, BioSTL, industry partners, and regional stakeholders to accelerate discovery, translation, workforce development, and community impact across the entire neuroscience ecosystem.
